Werewolf Therapeutics Inc. reported its third quarter 2025 financial results and issued a business update highlighting progress across its clinical pipeline. The company announced that it will provide an update on the interim data from the Phase 1/1b clinical trial of WTX-124, as well as insights from the End of Phase 1 meeting with the FDA, later in the fourth quarter of 2025. WTX-124, which recently received Fast Track Designation, is being evaluated for its path to a registration-enabling trial in advanced or metastatic cutaneous melanoma. Werewolf also plans to share an update on the Phase 1b/2 trial of WTX-330, including a potential further development plan, in the same timeframe. The company continues IND-enabling studies for WTX-1011, its first INDUCER™ T-cell engager targeting STEAP1, and expects to nominate a differentiated target candidate by year-end. Additionally, Werewolf will present pharmacokinetic data on WTX-124 at the 2025 SITC Annual Meeting.